Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 1.19
NAVB's Cash to Debt is ranked higher than
58% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. NAVB: 1.19 )
NAVB' s 10-Year Cash to Debt Range
Min: 0.28   Max: 103.57
Current: 1.19

0.28
103.57
Equity to Asset -0.10
NAVB's Equity to Asset is ranked lower than
60% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. NAVB: -0.10 )
NAVB' s 10-Year Equity to Asset Range
Min: -1.09   Max: 0.87
Current: -0.1

-1.09
0.87
F-Score: 3
Z-Score: -10.43
M-Score: 12.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -3398.59
NAVB's Operating margin (%) is ranked lower than
60% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. NAVB: -3398.59 )
NAVB' s 10-Year Operating margin (%) Range
Min: -35429.11   Max: 13.25
Current: -3398.59

-35429.11
13.25
Net-margin (%) -3775.33
NAVB's Net-margin (%) is ranked lower than
60% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. NAVB: -3775.33 )
NAVB' s 10-Year Net-margin (%) Range
Min: -36907.59   Max: 938.63
Current: -3775.33

-36907.59
938.63
ROA (%) -105.91
NAVB's ROA (%) is ranked lower than
59% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. NAVB: -105.91 )
NAVB' s 10-Year ROA (%) Range
Min: -459.96   Max: 24.3
Current: -105.91

-459.96
24.3
ROC (Joel Greenblatt) (%) -1808.85
NAVB's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. NAVB: -1808.85 )
NAVB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5206.05   Max: 148.79
Current: -1808.85

-5206.05
148.79
EBITDA Growth (%) -22.60
NAVB's EBITDA Growth (%) is ranked higher than
57% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. NAVB: -22.60 )
NAVB' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 141
Current: -22.6

0
141
EPS Growth (%) -23.10
NAVB's EPS Growth (%) is ranked higher than
58% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. NAVB: -23.10 )
NAVB' s 10-Year EPS Growth (%) Range
Min: 0   Max: 112.7
Current: -23.1

0
112.7
» NAVB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013
Q2 2013
Q4 2013
» Details

Insider Trades

Latest Guru Trades with NAVB



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
EV-to-EBIT -6.60
NAVB's EV-to-EBIT is ranked higher than
97% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. NAVB: -6.60 )
NAVB' s 10-Year EV-to-EBIT Range
Min: 4.2   Max: 50.9
Current: -6.6

4.2
50.9

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 24.40
NAVB's Earnings Yield (Greenblatt) is ranked higher than
97% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. NAVB: 24.40 )
NAVB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 29.7
Current: 24.4

2
29.7
Forward Rate of Return (Yacktman) 100.48
NAVB's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. NAVB: 100.48 )
NAVB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -231.1   Max: -88.5
Current: 100.48

-231.1
-88.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Navidea Biopharmaceuticals Inc is incorporated in Delaware. It is a biopharmaceutical company which is engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Gamma Detection Devices; Blood Flow Measurement Devices. Since October of 1999, its gamma detection systems have been marketed and distributed through Ethicon Endo-Surgery, Inc. 'EES', a Johnson & Johnson company. It has two radiopharmaceutical products, Lymphoseek and RIGScan, in advanced phases of clinical development. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
comment on NAVB Mar 15 2013 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide